Skip Nav Destination
Issues
1 July 2017
-
Cover Image
Cover Image
ABOUT THE COVER
FISH probes were used to distinguish human and mouse cells in a patient-derived xenograft. This demonstrates rapid stromal replacement by murine cells. The dual-color fluorescence image highlights nuclei from human (painted in red) and from mouse (painted in green) origin. For more details, see article by Katsiampoura and colleagues on page 1435. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1535-7163
EISSN 1538-8514
Highlights
Review
Small Molecule Therapeutics
Novel Indole-based Tambjamine-Analogues Induce Apoptotic Lung Cancer Cell Death through p38 Mitogen-Activated Protein Kinase Activation
Pilar Manuel-Manresa; Luís Korrodi-Gregório; Elsa Hernando; Alberto Villanueva; David Martínez-García; Ananda M. Rodilla; Ricard Ramos; Margarida Fardilha; Juan Moya; Roberto Quesada; Vanessa Soto-Cerrato; Ricardo Pérez-Tomás
Discovery and Characterization of Novel Nonsubstrate and Substrate NAMPT Inhibitors
Julie L. Wilsbacher; Min Cheng; Dong Cheng; Samuel A.J. Trammell; Yan Shi; Jun Guo; Stormy L. Koeniger; Peter J. Kovar; Yupeng He; Sujatha Selvaraju; H. Robin Heyman; Bryan K. Sorensen; Richard F. Clark; T. Matthew Hansen; Kenton L. Longenecker; Diana Raich; Alla V. Korepanova; Steven Cepa; Danli L. Towne; Vivek C. Abraham; Hua Tang; Paul L. Richardson; Shaun M. McLoughlin; Ilaria Badagnani; Michael L. Curtin; Michael R. Michaelides; David Maag; F. Gregory Buchanan; Gary G. Chiang; Wenqing Gao; Saul H. Rosenberg; Charles Brenner; Chris Tse
Author Choice
Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Hsu-Ping Kuo; Scott A. Ezell; Karl J. Schweighofer; Leo W.K. Cheung; Sidney Hsieh; Mutiah Apatira; Mint Sirisawad; Karl Eckert; Ssucheng J. Hsu; Chun-Te Chen; Darrin M. Beaupre; Matthias Versele; Betty Y. Chang
MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody
Pamela J. Farrell; Jennifer Matuszkiewicz; Deepika Balakrishna; Shweta Pandya; Mark S. Hixon; Ruhi Kamran; Shaosong Chu; J. David Lawson; Kengo Okada; Akira Hori; Akio Mizutani; Hidehisa Iwata; Ron de Jong; Barbara Hibner; Patrick Vincent
Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes PTEN/TP53-Deficient Prostate Cancer to Radiation
Anne L. van de Ven; Shifalika Tangutoori; Paige Baldwin; Ju Qiao; Codi Gharagouzloo; Nina Seitzer; John G. Clohessy; G. Mike Makrigiorgos; Robert Cormack; Pier Paolo Pandolfi; Srinivas Sridhar
ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non–Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms
Marie D. Ralff; Christina L.B. Kline; Ozan C. Küçükkase; Jessica Wagner; Bora Lim; David T. Dicker; Varun V. Prabhu; Wolfgang Oster; Wafik S. El-Deiry
Large Molecule Therapeutics
Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody–Drug Conjugate REGN2878-DM1 in PRLR-Positive Breast Cancers
Marcus P. Kelly; Carlos Hickey; Sosina Makonnen; Sandra Coetzee; Sumreen Jalal; Yu Wang; Frank Delfino; Jing Shan; Terra B. Potocky; Ishita Chatterjee; Julian Andreev; Arthur Kunz; Christopher D'Souza; Jason T. Giurleo; Thomas Nittoli; Pamela A. Trail; Gavin Thurston; Jessica R. Kirshner
Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3
Christophe Le Clorennec; Hervé Bazin; Olivier Dubreuil; Christel Larbouret; Charline Ogier; Yassamine Lazrek; Véronique Garambois; Marie-Alix Poul; Philippe Mondon; Jean-Marc Barret; Gérard Mathis; Jean-François Prost; André Pèlegrin; Thierry Chardès
Cancer Biology and Signal Transduction
Genomic and Molecular Screenings Identify Different Mechanisms for Acquired Resistance to MET Inhibitors in Lung Cancer Cells
Pol Gimenez-Xavier; Eva Pros; Ester Bonastre; Sebastian Moran; Ana Aza; Osvaldo Graña; Gonzalo Gomez-Lopez; Sophia Derdak; Marc Dabad; Anna Esteve-Codina; Jose R. Hernandez Mora; Diana Salinas-Chaparro; Manel Esteller; David Pisano; Montse Sanchez-Cespedes
Author Choice
Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer
Michael A. Gordon; Nicholas C. D'Amato; Haihua Gu; Beatrice Babbs; Julia Wulfkuhle; Emanuel F. Petricoin; Isela Gallagher; Ting Dong; Kathleen Torkko; Bolin Liu; Anthony Elias; Jennifer K. Richer
Companion Diagnostics and Cancer Biomarkers
Author Choice
Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer
Young Kwang Chae; Andrew A. Davis; Sarika Jain; Cesar Santa-Maria; Lisa Flaum; Nike Beaubier; Leonidas C. Platanias; William Gradishar; Francis J. Giles; Massimo Cristofanilli
Author Choice
Histone Methyltransferase G9a Drives Chemotherapy Resistance by Regulating the Glutamate–Cysteine Ligase Catalytic Subunit in Head and Neck Squamous Cell Carcinoma
Chia-Wen Liu; Kuo-Tai Hua; Kai-Chun Li; Hsiang-Fong Kao; Ruey-Long Hong; Jenq-Yuh Ko; Michael Hsiao; Min-Liang Kuo; Ching-Ting Tan
Models and Technologies
Modeling of Patient-Derived Xenografts in Colorectal Cancer
Anastasia Katsiampoura; Kanwal Raghav; Zhi-Qin Jiang; David G. Menter; Andreas Varkaris; Maria P. Morelli; Shanequa Manuel; Ji Wu; Alexey V. Sorokin; Bahar Salimian Rizi; Christopher Bristow; Feng Tian; Susan Airhart; Mingshan Cheng; Bradley M. Broom; Jeffrey Morris; Michael J. Overman; Garth Powis; Scott Kopetz
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds